Clinical Trial

Intestinal Permeability in Children With Autism Spectrum Disorder

Study acronym: IP-ASD
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 27, 2025 (before its estimated September 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
In recent years, increasing attention has been directed toward the role of the gut-brain axis in the pathogenesis of neurodevelopmental disorders, particularly Autism Spectrum Disorder (ASD). Among the multiple contributing factors, the integrity of the intestinal barrier appears to play a crucial role. Enhanced paracellular permeability ("leaky gut") may allow luminal antigens and microbial metabolites to translocate into the systemic circulation, triggering inflammatory responses that could impact neuropsychological functioning. Several studies suggest that, although intestinal permeability is not universally altered in all individuals with ASD, there exists a subset characterized by selective epithelial dysfunction, especially associated with repetitive and stereotyped behaviors. This project aims to investigate, through a controlled sibling-based design, whether intestinal permeability indices are significantly altered in children with ASD and whether such alterations are specifically correlated with behavioral domains assessed through the ADOS instrument.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-18.
Trial Details
NCT Number NCT07032857
Lead Sponsor University of Bari
Conditions Autism Spectrum Disorders
Enrollment 55 participants
Start Date 2023-01-01
Primary Completion 2025-09-30 (estimated)
Study Completion 2025-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-06-27